will immune checkpoint inhibitors become the new standard of care for urothelial cancer?
Published 6 years ago • 99 plays • Length 1:29Download video MP4
Download video MP3
Similar videos
-
2:01
immune checkpoint inhibitors in urothelial bladder cancer
-
2:57
immune-checkpoint inhibitors for urothelial cancer
-
1:56
immune checkpoint inhibitors for urothelial carcinoma: the current landscape
-
2:57
when can checkpoint inhibitors be used to treat urothelial carcinoma?
-
1:28
immune checkpoint inhibitors and sitravatinib in bladder cancer
-
1:05
limitations in immune checkpoint inhibitors in treating gastric cancer
-
4:11
what's next for checkpoint inhibitors in metastatic urothelial bladder cancer?
-
1:14
how can we continue the success of checkpoint inhibitors for bladder cancer treatment?
-
3:30
side effects of immune checkpoint inhibitors
-
0:57
how do we select the urothelial carcinoma patients who will benefit from checkpoint inhibitors?
-
2:41
should pd-l1 be used as a biomarker for immunotherapy in bladder cancer?
-
6:00
use of immune checkpoint inhibitors for bladder cancer
-
4:43
impact of immune checkpoint inhibitors on care of patients with advanced bladder cancer
-
2:05
the evolving treatment landscape of advanced and metastatic urothelial carcinoma
-
3:31
the use of immunotherapy as a first-line therapy for bladder cancer
-
2:01
using checkpoint inhibitors at earlier stages of bladder cancer – the next step in immunotherapy?
-
1:39
checkpoint inhibitors for metastatic urothelial cancer
-
43:46
checkpoint inhibitors: a new frontier in bladder cancer
-
0:58
strategies for optimizing immune checkpoint inhibition in urothelial carcinoma